GlaxoSmithKline drops anti-obesity drug as profits fall
Friday 11 February 2005
Jean Pierre Garnier, the chief executive, said 2004 was "always going to be a tough year" for the company as many of its patents ran out, opening the door for rival generic versions of its drugs to go on sale. It also announced it had dropped the development of an anti-obesity drug, after clinical trials proved disappointing.
Sales across the group fell 5 per cent to pounds 20.3bn in 2004, hit by generic rivals to its antidepressants Wellbutrin and Paxil. Pre-tax profits for the year declined 9 per cent to pounds 6.1bn. Mr Garnier said the group had taken the worst hit from generic drugs for some years, and it now had 15 key new drugs that are due to produce crucial testing results in 2005. "We are going to find out if all our efforts to develop our pipeline will pay off," he said.
One of this year's most eagerly awaited findings will be test results of its latest HIV treatment. Dr Tachi Yamada, the head of research and development, said: "Many people think HIV is purely a problem in the developing world, but it is still an issue across the globe."
Most HIV treatments attempt to kill the virus, but GSK's treatment targets the cells the HIV virus infects, preventing it from spreading.
Mr Garnier said investors had underestimated the potential for its cervical cancer treatment, which it hopes will vaccinate millions of women against the disease. It is due to enter its final testing phase, and GSK claims it could eradicate 70 per cent of cervical cancer cases. "Most analyst consensus on the Cervarix vaccine is too low. Demand is going to expand dramatically," he said. Analysts are forecasting sales of $1bn.
Another vaccine GSK is pinning its hopes on this year works against the most common cause of diarrhoea, which infects 125 million children and kills 440,000 people a year.
The company released the findings of a study into its asthma treatment yesterday, which compared its success with a similar drug from its rival AstraZeneca. GSK claims research into the effectiveness of Seretide showed its patients had about an extra 24 days free from symptoms than patients taking AstraZeneca's Symbicort.
- 1 Alan Rickman admits editing 'terrible' script with friends in Pizza Hut behind backs of writers on Robin Hood: Prince of Thieves
- 2 Rarest Beanie Baby of them all could be sold for £62,500 on eBay
- 3 Professional big game hunter Ian Gibson crushed to death by elephant during hunt
- 4 Farmer told to tear down mock-Tudor castle after hiding construction behind hay bales
- 5 Rebecca Francis accuses Ricky Gervais of using 'influence' to target female hunters after receiving barrage of death threats
Yemen crisis: Meet the child soldiers who have forsaken books for Kalashnikovs
Alan Rickman admits editing 'terrible' script with friends in Pizza Hut behind backs of writers on Robin Hood: Prince of Thieves
Rarest Beanie Baby of them all could be sold for £62,500 on eBay
Professional big game hunter Ian Gibson crushed to death by elephant during hunt
Farmer told to tear down mock-Tudor castle after hiding construction behind hay bales
If I’m being racially abused I don’t need a stranger with a saviour complex to rescue me
The only black face in the Ukip manifesto is on the page about overseas aid
Ukip is the only main political party to not address LGBT rights in its manifesto
Food banks: One million Britons will soon be using them, according to Trussell Trust
Religion isn't growing, it is becoming vigorous in its demise, says philosopher AC Grayling
BBC election debate: The one photo that summed up the whole 90-minute leaders debate
iJobs Money & Business
£20000 - £25000 per annum + OTE £45,000: SThree: SThree Group have been well e...
£50000 - £667000 per annum + excellent benefits : Ashdown Group: IT Manager / ...
£13000 - £20000 per annum: Recruitment Genius: Scotland's leading life insuran...
£40000 - £45000 per annum + benefits : Ashdown Group: Training Programme Manag...